Mad Money Mailbag: A Prescription for Centene

A viewer learns how Cramer would treat the healthcare company.
Author:
Publish date:

Editor's note: The following are questions received from viewers of "Mad Money," seen every day at 6 p.m. EST on CNBC.

What are your latest thoughts on Centene (CNC) - Get Report?-- Erik from Arkansas

James J. Cramer:

I like this company very much, but like most Medicaid plays the stock has been volatile of late. Centene could be an attractive buy up to $25, though a more conservative play would be to first look at the fourth quarter results that are due out Feb. 7.

Want more Cramer? Check out Jim's rules and commandments for investing from his latest book by

clicking here

.